Cost-effectiveness of treating acute coronary syndrome patients with ticagrelor for 12 months: results from the PLATO study
2013 (English)In: European Heart Journal, ISSN 0195-668X, E-ISSN 1522-9645, Vol. 34, no 3, 220-228 p.Article in journal (Refereed) Published
The efficacy and safety of ticagrelor vs. clopidogrel in patients with acute coronary syndromes (ACS) are well documented in the PLATelet inhibition and patient Outcomes trial (PLATO). The aim of this study was to assess the long-term cost-effectiveness of treating ACS patients for 12 months with ticagrelor compared with generic clopidogrel.less thanbrgreater thanless thanbrgreater thanEvent rates, health-care costs, and health-related quality of life during 12 months of therapy with either ticagrelor or generic clopidogrel were estimated from PLATO. Beyond 12 months, quality-adjusted survival and costs were estimated conditional on whether a non-fatal myocardial infarction (MI), a non-fatal stroke, or no MI or stroke occurred during the 12 months of therapy. Lifetime costs, life expectancy, and quality-adjusted life years (QALYs) were estimated for both treatment strategies. Incremental cost-effectiveness ratios were presented from a health-care perspective in 2010 Euros (Euro) applying unit costs and life tables from a Swedish setting in the base-case analysis. Treatment with ticagrelor was associated with increased health-care costs of Euro362 and a QALY gain of 0.13 compared with generic clopidogrel, yielding a cost per QALY gained with ticagrelor of Euro2753. The cost per life year gained was Euro2372. The results were consistent in major subgroups. Sensitivity analyses showed a cost per QALY gained with ticagrelor of approximate to Euro7300 under certain scenarios.less thanbrgreater thanless thanbrgreater thanBased on clinical and health-economic evidence from the PLATO study, treating ACS patients with ticagrelor for 12 months is associated with a cost per QALY below generally accepted thresholds for cost-effectiveness.less thanbrgreater thanless thanbrgreater thanClinicalTrials.gov Identifier: NCT00391872.
Place, publisher, year, edition, pages
Oxford University Press (OUP): Policy B , 2013. Vol. 34, no 3, 220-228 p.
Acute coronary syndrome, Ticagrelor, Clopidogrel, Cost-effectiveness analysis, Quality-adjusted life years
Medical and Health Sciences
IdentifiersURN: urn:nbn:se:liu:diva-89531DOI: 10.1093/eurheartj/ehs149ISI: 000313831000013OAI: oai:DiVA.org:liu-89531DiVA: diva2:608215
Funding Agencies|AstraZeneca||Pfizer||Boehringer Ingelheim||Bristol-Myers Squibb||GlaxoSmithKline||Schering-Plough||Regado Biotechnologies||Athera Biotechnologies||Eli Lilly||2013-02-262013-02-262013-09-11